Puregon®

FSH - recombinante folitropina beta

Resultados demostrados - Experiencia comprobada.

La prueba está en los números

Eficacia comprobada en el mayor de los ensayos clínicos de FIV.[1]

- Resultados comprobados: 38% de embarazos en curso.[1]
- Excelentes tasas de embarazo independientes del nivel de LH endógena.[1]
- Óptima flexibilidad posológica, aplicador de fácil uso.[2-5]

Referencias: 1. Doody K, Witjes H, Mannaerts S, Gordon K. Success rates of a fixed rFSH/GnRH antagonist protocol are not affected by endogenous LH levels. Abstract presented at: the 25th Annual Meeting of the European Society of Human Reproduction and Embryology; June 28-July 1,2009; Amsterdam, The Netherlands. 2. Platteau P, Laurent E, Albano C, et al. An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by conventional syringe in women undergoing ovarian slimulation for IVF/ICSI. Hum Reprod. 2003;18(6):1200-4. 3. Rama Raju GA, Suryanarayana K, Prakash GJ, Krishna KM. Com-parison of follitropin beta administered by a pen device with conventional syringe in an ART programme. J Clin Pharm Ther. 2008;33:401-407. 4. Kettel LM, Scholl G, Bonaventura L, et al. Evaluation of a pen device for selfadminisiration of recombinant human FSH in clomiphene citrate-resistant anovulatory women undergoing ovulation induction. Repro Biomed Online. 2004;9(4):373-380. 5. Pang S, Kaplan B, Karande V, et al. Administration of recombinant human FSH (solution In cartridge) with a pen device in women undergoing ovarian slimulation. Repro Biomed Online 2003;7(3): 319-326.

MSD

MSD ARGENTINA S.R.L.
Cazadores de Coquimbo 2841/57, Piso 4
(B1605AZE) - Munro - Vicente López - Bs. As. /
Tel.: 11-6090-7200 // www.msd.com.ar
03-2018 WOMN-1176916-0000